Dr. Petrylak Discusses the Future of Abiraterone Acetate

Daniel P. Petrylak, MD
Published: Friday, Apr 27, 2012

Daniel P. Petrylak, MD, Professor of Medicine, Program Director, Genitourinary Oncology Section, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, expects exciting information to be presented at the 2012 ASCO Annual Meeting on abiraterone acetate (Zytiga), for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.

Early evidence from the phase III COU-AA-302 trial suggests that the combination of abiraterone acetate and prednisone improves progression-free survival and is showing trends towards an improvement in overall survival.

Abiraterone acetate is currently approved following progression on chemotherapy. Petrylak feels that data from the COU-AA-302 trial will justify the early use of abiraterone acetate and that it may replace ketoconazole as the first hormone therapy that patients receive following disease progression.

Daniel P. Petrylak, MD, Professor of Medicine, Program Director, Genitourinary Oncology Section, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, expects exciting information to be presented at the 2012 ASCO Annual Meeting on abiraterone acetate (Zytiga), for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.

Early evidence from the phase III COU-AA-302 trial suggests that the combination of abiraterone acetate and prednisone improves progression-free survival and is showing trends towards an improvement in overall survival.

Abiraterone acetate is currently approved following progression on chemotherapy. Petrylak feels that data from the COU-AA-302 trial will justify the early use of abiraterone acetate and that it may replace ketoconazole as the first hormone therapy that patients receive following disease progression.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x